Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a daily powder boost iron levels in women? new study investigates

NCT ID NCT05990166

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a mineral-enriched powder taken daily for six months could raise blood iron levels in women aged 18-35 with iron deficiency. Participants mixed the powder or a placebo into water and provided blood samples monthly. The goal was to see if the powder reduces the number of women who remain iron deficient after six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mineral-enriched powder containing ferrous iron and zinc sulfate monohydrate
What this could lead to
If it works, this could offer a simple, at-home way to improve iron levels and reduce iron deficiency in women of reproductive age.
What could go wrong
This is a small, early-phase trial with only 150 participants. The powder may not significantly raise iron levels compared to placebo, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

150 people

The number who actually took part.

Started

Apr 2023

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non-pregnant and non-lactating * English speaking with the ability to give informed consent * 18-35 years of age (inclusive) * Women who are biologically female * Iron deficient (SF \>/=12μg/L and \</=30 μg/L). Note: there is currently poor consensus on diagnostic criteria for iron deficiency based on SF concentrations. Current recommendations range from 15 μg/L to 100 μg/L. * Hb \>/=110 g/L * Willing and able to agree to the requirements and lifestyle restrictions of this study * Able to understand and read the questionnaires in English and carry out all study-related procedures * Located in the greater Ottawa area and a resident of Ontario Exclusion Criteria: * Individuals who are lactating, pregnant, or planning to become pregnant during the study * Individuals who are not maintaining adequate birth control measures * Adequate birth control measures include any option that will adequately prevent pregnancy including: contraceptives, lifestyle choices, complete abstinence, or as a result of other medical methods, procedures, or conditions * Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients * Are using vitamin and mineral supplements containing iron and/or zinc * SF concentrations \<12 μg/L or \>30 μg/L * Having moderate or severe anaemia (Hb \<109 g/L) * Expecting to change diet and exercise regimen in the next 6 months * Are frequent blood donors * Have donated blood in the last four months * Donate blood more than two to three times per year * Had major surgery in the past three months * Have planned surgery during the course of the study * History of problematic alcohol or substance use in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program) * Use of investigational product(s) in another research study within 30 days prior to the baseline visit or during the study duration * Using any of the following drugs: * Antacids or proton pump inhibitors, H2 blockers * Salicylates, aspirin, corticosteroids, nonsteroidal anti-inflammatory drugs * Anticoagulants, antiplatelet compounds * Drugs with known contraindication with iron supplementation or fortification * Antiviral medications * Levothyroxine (Synthroid) * Known medical history of specific conditions including: * Gastrointestinal disorders: celiac disease, ulcerative colitis, and Crohn's disease * Gastric cancer and gastric polyps * Colon cancer * Diverticular bleeding * Inflammatory bowel diseases * Angiodysplasia * Helicobacter pylori infection * Hookworm (Ancylostoma duodenale and Necator americanus) * Defects of hemostasis (hereditary hemorrhagic telangectasia, von Willebrand disease) * Gastrectomy, duodenal bypass, bariatric surgery * Erythropoiesis-stimulating agent therapy * Chronic kidney disease * Hemochromatosis * Hemoglobinopathies * Blood clotting disorder * Have any other active or unstable medical conditions or use of medications/supplements/ therapies that according to the scientific literature, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant or the quality of the study data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Iron deficiency anaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Iron Deficiencies iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Carleton University

    Ottawa, Ontario, K1S 5B6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.